Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
- Registration Number
- NCT00790998
- Lead Sponsor
- Medicines Development for Global Health
- Brief Summary
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1497
- Male and female subjects with Onchocerca volvulus infection
- Pregnant or breast feeding women; coincidental loiasis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Moxidectin Moxidectin Moxidectin 8mg Ivermectin Ivermectin Ivermectin 150 mcg/kg
- Primary Outcome Measures
Name Time Method skin microfilaria density (mf/mg) 12 months
- Secondary Outcome Measures
Name Time Method skin microfilaria density (mf/mg) 18 months skin microfilaria reduction from baseline 18 months proportion of subjects with undetectable levels of skin microfilaria 18 months percent reduction in microfilaria levels in the anterior chamber of the eye 12 months
Trial Locations
- Locations (4)
Centre de Recherche en Maladies Tropicales de l'Ituri
🇨🇩Rethy, Congo, The Democratic Republic of the
Liberian Institute for Biomedical Research Clinical Research Center
🇱🇷Bolahun, Lofa County, Liberia
Centre de Recherche Clinique de Butembo - Université Catholique du Graben
🇨🇩Butembo, Congo, The Democratic Republic of the
Onchocerciasis Chemotherapy Research Center
🇬🇭Hohoe, Ghana